Cargando…

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity

BACKGROUND: Antiprogestin compounds have been shown to be effective in blocking the growth of ovarian cancer cells of different genetic backgrounds. Herein we studied the anti-ovarian cancer effect of a series of antiprogestins sharing the chemical backbone of the most characterized antiprogestin, m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gamarra-Luques, Carlos D, Hapon, Maria B, Goyeneche, Alicia A, Telleria, Carlos M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007005/ https://www.ncbi.nlm.nih.gov/pubmed/24795781 http://dx.doi.org/10.1186/1757-2215-7-45

Ejemplares similares

Antiprogestins in gynecological diseases
por: Goyeneche, Alicia A, et al.
Publicado: (2015)

Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity
por: Freeburg, Elizabeth M, et al.
Publicado: (2009)

Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
por: Goyeneche, Alicia A, et al.
Publicado: (2012)

Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2
por: Goyeneche, Alicia A., et al.
Publicado: (2011)

Short term hypothyroidism affects ovarian function in the cycling rat
por: Hapon, María Belén, et al.
Publicado: (2010)

Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression
por: Tieszen, Chelsea R, et al.
Publicado: (2011)

Synergistic Lethality of Mifepristone and LY294002 in Ovarian Cancer Cells
por: Wempe, Stacy L., et al.
Publicado: (2013)

Mifepristone inhibits non-small cell lung carcinoma cellular escape from DNA damaging cisplatin
por: Kapperman, Heather E., et al.
Publicado: (2018)

Antioxidant and Anti-atherogenic Properties of Prosopis strombulifera and Tessaria absinthioides Aqueous Extracts: Modulation of NADPH Oxidase-Derived Reactive Oxygen Species
por: Quesada, Isabel, et al.
Publicado: (2021)

New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach
por: Woźniczka, Magdalena, et al.
Publicado: (2021)

High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
por: Lisio, Michael-Antony, et al.
Publicado: (2019)

Long-term primary culture of a clear cell ovarian carcinoma reveals an epithelial–mesenchymal cooperative interaction
por: Goyeneche, Alicia A., et al.
Publicado: (2015)

Prosopis strombulifera aqueous extract reduces T cell response and ameliorates type I diabetes in NOD mice
por: Persia, Fabio Andrés, et al.
Publicado: (2022)

Exogenous estradiol enhances apoptosis in regressing post-partum rat corpora lutea possibly mediated by prolactin
por: Goyeneche, Alicia A, et al.
Publicado: (2005)

Nelfinavir Induces Cytotoxicity towards High-Grade Serous Ovarian Cancer Cells, Involving Induction of the Unfolded Protein Response, Modulation of Protein Synthesis, DNA Damage, Lysosomal Impairment, and Potentiation of Toxicity Caused by Proteasome Inhibition
por: Subeha, Mahbuba R., et al.
Publicado: (2021)

The metastatic capacity of high-grade serous ovarian cancer cells changes along disease progression: inhibition by mifepristone
por: Ritch, Sabrina J., et al.
Publicado: (2022)

Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women
por: Bartlett, Thomas E., et al.
Publicado: (2022)

UHPLC–Q/Orbitrap/MS/MS fingerprinting and antitumoral effects of Prosopis strombulifera (LAM.) BENTH. queous extract on allograft colorectal and melanoma cancer models
por: Persia, Fabio Andrés, et al.
Publicado: (2020)

Correction: Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women
por: Bartlett, Thomas E., et al.
Publicado: (2022)

The Capacity of High-Grade Serous Ovarian Cancer Cells to Form Multicellular Structures Spontaneously along Disease Progression Correlates with Their Orthotopic Tumorigenicity in Immunosuppressed Mice
por: Goyeneche, Alicia, et al.
Publicado: (2020)

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
por: Ribeiro, J. R., et al.
Publicado: (2016)

Effects of paclitaxel and cisplatin on in vitro ovarian follicle development
por: Kim, Yoon Young, et al.
Publicado: (2019)

Auranofin Induces Lethality Driven by Reactive Oxygen Species in High-Grade Serous Ovarian Cancer Cells
por: Abdalbari, Farah H., et al.
Publicado: (2023)

Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein
por: Stordal, Britta, et al.
Publicado: (2012)

Hymenialdisine is Cytotoxic Against Cisplatin-Sensitive but Not Against Cisplatin-Resistant Cell Lines
por: Abdullah, Nada, et al.
Publicado: (2021)

Advanced assessment of migration and invasion of cancer cells in response to mifepristone therapy using double fluorescence cytochemical labeling
por: Ritch, Sabrina J., et al.
Publicado: (2019)

MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1
por: Sun, Kai-Xuan, et al.
Publicado: (2015)

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
por: Sherman-Baust, Cheryl A, et al.
Publicado: (2011)

Transcriptome Remodeling in Gradual Development of Inverse Resistance between Paclitaxel and Cisplatin in Ovarian Cancer Cells
por: Szenajch, Jolanta, et al.
Publicado: (2020)

Paclitaxel and SN‐38 Overcome Cisplatin Resistance of Ovarian Cancer Cell Lines by Down‐regulating the Influx and Efflux System of Cisplatin
por: Komuro, Yuuki, et al.
Publicado: (2001)

CHFR and Paclitaxel Sensitivity of Ovarian Cancer
por: Wahner Hendrickson, Andrea E., et al.
Publicado: (2021)

The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers
por: Goto, T, et al.
Publicado: (2008)

Potentiation of Cisplatin Cytotoxicity in Resistant Ovarian Cancer SKOV3/Cisplatin Cells by Quercetin Pre-Treatment
por: Hasan, Aseel Ali, et al.
Publicado: (2023)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023)

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin
por: Mesquita, Bárbara, et al.
Publicado: (2005)

Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells
por: Huang, Wei, et al.
Publicado: (2016)

Hederagenin potentiated cisplatin- and paclitaxel-mediated cytotoxicity by impairing autophagy in lung cancer cells
por: Wang, Kun, et al.
Publicado: (2020)

Anticancer effects of mifepristone on human uveal melanoma cells
por: Alvarez, Prisca Bustamante, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e5n1ikqm7nmpm4s906vku8k8rm